期刊
ONCOTARGET
卷 6, 期 30, 页码 30130-30148出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4967
关键词
HCC; VRK1; proliferation; cell cycle; luteolin
资金
- National R&D Program for Cancer Control
- Ministry for Health and Welfare, Republic of Korea [1320240]
- National Research Foundation of Korea (NRF) grant - Korea government (MEST) [2014R1A2A2A01002931]
- Next-Generation Bio-Green 21 Program
- Rural Development Administration, Republic of Korea [PJ01121601]
- BK21 Plus - Ministry of Education, Korea [10Z20130012243]
- National Research Foundation of Korea [2014R1A2A2A01002931] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
We identified the specific role of vaccinia-related kinase 1 (VRK1) in the progression of hepatocellular carcinoma (HCC) and evaluated its therapeutic and prognostic potential. VRK1 levels were significantly higher in HCC cell lines than a normal hepatic cell line, and were higher in HCC than non-tumor tissue. VRK1 knockdown inhibited the proliferation of SK-Hep1, SH-J1 and Hep3B cells; moreover, depletion of VRK1 suppressed HCC tumor growth in vivo. We also showed that VRK1 knockdown increased the number of G1 arrested cells by decreasing cyclin D1 and p-Rb while upregulating p21 and p27, and that VRK1 depletion downregulated phosphorylation of CREB, a transcription factor regulating CCND1. Additionally, we found that luteolin, a VRK1 inhibitor, suppressed HCC growth in vitro and in vivo, and that the aberrant VRK1 expression correlated with poor prognostic features of HCC. High levels of VRK1 were associated with shorter overall and disease-free survival and higher recurrence rates. Taken together, our findings suggest VRK1 may act as a tumor promoter by controlling the level of cell cycle regulators associated with G1/S transition and could potentially serve as a therapeutic target and/or prognostic biomarker for HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据